Branded Generics Market

Branded generic is a generic drug, which is manufactured by either original manufacturer after patent expiry of the brand, or is manufactured by a generic manufacturer. Branded generic has to go through abbreviated new drug application (ANDA) process before it can be marketed. Branded generic are cheaper than their branded counterparts but can be costlier than generic versions of the drug. Branded generic is defined as a product that is a novel dosage form of a branded off-patent medicine, and is manufactured by a different manufacturer than originator, or a molecule copy of an off-patent product with a trade name. Branded generics can also be different salts of an FDA-approved brand name drug.

It is easy to confuse branded generics with authorized generics, but they are not the same. Branded generics go through the same FDA approval process as other generics after branded drug patents expire. Authorized generics, however, are created by makers of branded drugs, under the same NDA (New Drug Approval) authorization as the original branded drug, and they may be sold before drug patents expire.

Market Dynamics

Rising ANDA approvals is a major factor which is supporting the market growth. According to an article published by Delhi Pharmaceutical Sciences & Research University on March 7 2023, a total of 742 Abbreviated New Drug Application (ANDA) approvals were granted during the calendar year 2022, registering a growth of 17% over last year. Additionally, 136 Tentative Approvals were also granted, again a similar growth over 2021 numbers (117) as seen for final ANDA approvals. Indian players contributed a large proportion of the incremental number of approvals this year with 88 more approvals than last year. Additionally, demand for generic medications is in surge owing to the affordable prices of branded generics.

Key features of the study:

• This report provides an in-depth analysis of the global branded generics market and provides market size (US$ Million) and compound annual growth rate (CAGR) of 7.30% for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global branded generics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Aspen Pharmacare Holding Ltd., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global branded generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global branded generics market.

Detailed Segmentation:

• Global Branded Generics Market, By Drug Class:
  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others
• Global Branded Generics Market, By Formulation:
  • Oral
  • Parenteral
  • Topical
  • Others
• Global Branded Generics Market, By Indication:
  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Gastrointestinal Diseases
  • Dermatology Diseases
  • Analgesics and Anti-inflammatory
  • Others
• Global Branded Generics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Drug Stores Global Branded generics Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Mylan N.V
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aspen Pharmacare Holding Ltd.
  • Abbott Laboratories
  • Valeant Pharmaceuticals International, Inc